**General description**

Prednisolone is a synthetic glucocorticoid used in the treatment of various conditions where corticosteroids are indicated.

<table>
<thead>
<tr>
<th>INN</th>
<th>Prednisolone</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>H02AB06 S01BA04 A07EA01</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
<tr>
<td>EML status history</td>
<td>First added in 1984 (TRS 722) for Allergic or hypersensitivity conditions of unspecified type Added in 1984 (TRS 722) for Unspecified malignant neoplasms of ill-defined or unspecified sites Added in 1989 (TRS 796) for Scleritis Added in 1989 (TRS 796) for Anterior uveitis Added in 2011 (TRS 965) for Lymphoid leukaemia, not elsewhere classified Added in 2011 (TRS 965) for Burkitt lymphoma including Burkitt leukaemia Added in 2015 (TRS 994) for Follicular lymphoma Added in 2015 (TRS 994) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Added in 2015 (TRS 994) for Diffuse large B-cell lymphomas Added in 2015 (TRS 994) for Hodgkin lymphoma Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites Added in 2019 (TRS 1021) for Plasma cell myeloma Added in 2019 (TRS 1021) for Malignant neoplasms of prostate Changed in 2021 (TRS 1035) for Crohn disease site Added in 2021 (TRS 1035) for Ulcerative colitis Added in 2021 (TRS 1035) for Crohn disease site Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative Added in 2023 (TRS 1049) for Langerhans cell histiocytosis</td>
</tr>
<tr>
<td>Therapeutic equivalent for</td>
<td>hydrocortisone for Crohn disease, unspecified site</td>
</tr>
<tr>
<td>Wikipedia</td>
<td>Prednisolone</td>
</tr>
<tr>
<td>DrugBank</td>
<td>Prednisolone</td>
</tr>
</tbody>
</table>

**Recommendations**

**Section**

Antiallergics and medicines used in anaphylaxis

- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg

**Indications**

- Allergic or hypersensitivity conditions of unspecified type
**Hormones and antihormones**

Oral > Solid: 5 mg; 25 mg
Oral > Liquid: 5 mg per mL

**Indications**
- Follicular lymphoma
- Lymphoid leukaemia, not elsewhere classified
- Chronic lymphocytic leukaemia or small lymphocytic lymphoma
- Diffuse large B-cell lymphomas
- Hodgkin lymphoma
- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Burkitt lymphoma including Burkitt leukaemia
- Plasma cell myeloma
- Malignant neoplasms of prostate
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative
- Langerhans cell histiocytosis

**Ophthalmological preparations > Anti-inflammatory agents**

Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)

**Indications**
- Scleritis
- Anterior uveitis

**Anti-inflammatory medicines**

Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)

**Indications**
- Ulcerative colitis
- Crohn disease site